Alkermes plc (ALKS) Presents at Evercore 8th Annual Healthcare Conference Transcript
Alkermes plc (ALKS) Presents at Evercore 8th Annual Healthcare Conference Transcript
Fiscal Year: January - December
Alkermes plc (ALKS), listed on the NASDAQ, has a market capitalization of $. As of Dec 07, 2025, the stock is trading at $29.52 per share, offering investors a clear view of its current market value. Alkermes plc is a prominent player in the industry sector, attracting both institutional and retail investors due to its performance and potential.
With a P/E ratio of 14.67, investors can assess the stock's valuation in comparison to its earnings. A P/E ratio is a crucial indicator for value investors, showing whether the stock is over or undervalued relative to its current earnings. Alkermes plc also offers a dividend yield of N/A , making it an attractive option for income-focused investors who seek regular dividends.
Our Discounted Cash Flow (DCF) analysis reveals that Alkermes plc (ALKS) may be undervalued compared to its intrinsic worth. However, to see the exact DCF fair value, please Login or Upgrade for access.
The proprietary SS Score for Alkermes plc is a unique metric that analyzes the company's financial health and growth potential. The score takes into account critical factors such as revenue growth, net income, free cash flow (FCF) compound annual growth rate (CAGR), the trend of shares outstanding, and the debt-to-FCF ratio. This helps investors to make a more informed decision, as an undervalued stock might still have poor financial fundamentals.
To view the detailed SS Score for Alkermes plc, Login or Upgrade for access.
The Price to Free Cash Flow (P/FCF) ratio for Alkermes plc is 9.93, offering insights into how much investors are paying for the company's free cash flow. A lower P/FCF ratio typically suggests that the stock is undervalued, while a higher ratio may indicate overvaluation.
In summary, Alkermes plc (ALKS) has shown consistent financial performance, as illustrated by the financial charts above, which track its revenue growth, net income, free cash flow, and shares outstanding over the past several years. These metrics provide investors with key insights into the company's past and projected future performance. Investors should use the SS Score alongside the DCF Fair Value to make better-informed decisions about whether to buy or hold the stock.
*This analysis is for informational purposes only and does not constitute investment advice. Always read the company's 10-K filings and do your own research before making any investment decisions.
Whether Alkermes plc (ALKS) is a good stock to buy depends on various factors, including its financial health, market conditions, and your investment strategy. Our analysis indicates that the stock may be undervalued compared to its intrinsic value. However, it is important to assess the SS Score and review the company's fundamentals before making any investment decisions.
The fair value of Alkermes plc (ALKS) is determined through our Discounted Cash Flow (DCF) analysis. This value represents the intrinsic worth of the stock based on its expected future cash flows. To view the specific fair value, consider subscribing to our service for complete access.
The SS Score is a proprietary financial quality metric that assesses factors such as revenue growth, net income, free cash flow growth, and debt levels. It helps investors evaluate the overall financial health of Alkermes plc. To access the full SS Score, consider upgrading your subscription.
Alkermes plc is a significant player in the industry sector, with a market capitalization of $ and a competitive P/E ratio of 14.67. Investors should compare these metrics with industry peers to gauge whether Alkermes plc is outperforming or underperforming within its sector.
Alkermes plc (ALKS) Presents at Evercore 8th Annual Healthcare Conference Transcript
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) announced today that management will participate in two upcoming investor conferences. 8th Annual Evercore Healthcare Conference Date/Time: Wednesd...
Alkermes said on Wednesday it has sweetened its offer to buy Avadel Pharmaceuticals , beating a rival bid from Denmark's Lundbeck and valuing the sleep disorder drugmaker at up to $2.37 billion.
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTIO...
Alkermes plc ( ALKS) Shareholder/Analyst Call November 12, 2025 8:30 AM EST Company Participants Sandra Coombs - Senior Vice President of Corporate Affairs & Investor Relations Richard F. Pops - Chai...
Avadel Pharmaceuticals plc (NASDAQ: AVDL) on Friday received an unsolicited proposal from H. Lundbeck A/S for up to $23.00 per ordinary share.
The unsolicited bid—worth up to $2.25 billion —potentially upends Avadel's deal to be acquired by Alkermes.
Alkermes said on Friday it is reviewing its options with advisers after Avadel Pharmaceuticals disclosed it had received an unsolicited takeover proposal from Danish pharmaceutical company Lundbeck.
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (IN WHOLE OR IN PART) DIRECTLY OR INDIRECTLY, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULAT...
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE MARKET ABUSE REGULATION (EU) 596/2014 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FR...
Alkermes plc (NASDAQ:ALKS) released topline results on Wednesday from the Vibrance-2 dose-ranging phase 2 study evaluating alixorexton (formerly ALKS 2680) in narcolepsy type 2 (NT2).
Alkermes said on Wednesday its experimental narcolepsy drug met the main goals in a mid-stage study.
– Alixorexton is the First Oral Orexin 2 Receptor Agonist to Demonstrate Efficacy in a Large Phase 2 Study in Patients With Narcolepsy Type 2, Supporting Advancement to Phase 3 – – Alixorexton Met the...
DUBLIN , Nov. 5, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS): IRISH TAKEOVER PANEL OPENING POSITION DISCLOSURE UNDER RULE 8.1(a) AND (b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 202...
Alkermes plc (NASDAQ:ALKS) Q3 2025 Earnings Call October 28, 2025 8:00 AM EDT Company Participants Sandra Coombs - Senior Vice President of Corporate Affairs & Investor Relations Richard F. Pops - Ch...
— Third Quarter Revenues of $394.2 Million — — GAAP Net Income of $82.8 Million and Diluted GAAP Earnings per Share of $0.49 — — Company Raises 2025 Financial Expectations — DUBLIN , Oct. 28,...
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of ...
On Wednesday, Alkermes plc (NASDAQ:ALKS) agreed to acquire Avadel Pharmaceuticals plc (NASDAQ:AVDL) for up to $20 per share in cash, which values Avadel at approximately $2.1 billion.
Alkermes plc (NASDAQ:ALKS) M&A Call October 22, 2025 8:00 AM EDT Company Participants Sandra Coombs - Senior Vice President of Corporate Affairs & Investor Relations Richard F. Pops - Chairman & CEO ...
Alkermes said on Wednesday it will acquire Avadel Pharmaceuticals for up to $2.1 billion gaining access to the company's approved excessive daytime sleepiness drug.
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTIO...
DUBLIN , Oct. 20, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (12:00 p.m.
DUBLIN , Sept. 12, 2025 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) is pleased to announce the appointment of Joshua Reed as Chief Financial Officer (CFO), effective Monday, Sept.
— Competitive Grant Program to Offer Individual Grants of Up to $100,000 per Project — — Areas of Interest Expanded to Include Sleep and Circadian Disturbances Associated With Bipolar I Disorder and/o...
Below estimates were sourced from SimplyWallSt and are intended for educational purposes only as a baseline for the analysis.
| Year | FCF Estimate | % | # Analysts |
|---|---|---|---|
| 2025 | 516.66M | 27.37% | Est @27.4% |
| 2026 | 627.67M | 21.49% | Analyst x5 |
| 2027 | 385.63M | -38.56% | Analyst x4 |
| 2028 | 434.90M | 12.78% | Analyst x4 |
| 2029 | 591.33M | 35.97% | Analyst x4 |
| 2030 | 592.03M | 0.12% | Est @0.1% |
| 2031 | 596.87M | 0.82% | Est @0.8% |
| 2032 | 604.66M | 1.31% | Est @1.3% |
| 2033 | 614.64M | 1.65% | Est @1.7% |
| 2034 | 625.48M | 1.76% | Est @1.8% |
Below are the FCF estimates with the discount factor and the calculated present value with the terminal value that led the results above.
| Year | FCF | Discount Factor | PV of Future FCF |
|---|---|---|---|
| 2023A | 353.31M | 1.00 | 353.31M |
| 2024A | 405.64M | 1.00 | 405.64M |
| 2025E | 516.66M | 1.08 | 479.15M |
| 2026E | 627.67M | 1.16 | 539.86M |
| 2027E | 385.63M | 1.25 | 307.60M |
| 2028E | 434.90M | 1.35 | 321.72M |
| 2029E | 591.33M | 1.46 | 405.69M |
| 2030E | 592.03M | 1.57 | 376.69M |
| 2031E | 596.87M | 1.69 | 352.21M |
| 2032E | 604.66M | 1.83 | 330.90M |
| 2033E | 614.64M | 1.97 | 311.95M |
| 2034E | 625.48M | 2.12 | 294.41M |
| Terminal | 12.04B | 2.12 | 5.67B |
The information given by Studying Stocks and provided in the web and/or mobile applications (Platforms) is only factual information and should not be considered financial advice.
Any information contained in this website has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
When creating an account, you acknowledge that you are:
We retain the right to cancel your account for any reason, or refuse your account creation request.
The information on our Platforms is not comprehensive and is intended to provide a summary of the subject matter covered. While we use all reasonable attempts to ensure the accuracy and completeness of the data and information on our Platforms, to the extent permitted by law, we make no warranty regarding the information on these Platforms. You should monitor any changes to the information contained on these Platforms.
Furthermore we make no commitments in regards to the minimum amount of uptime that our platforms will maintain, although we will make ever reasonable attempt to ensure that the platforms are operational. Therefore, any reference of "latest", "current" and related words about the financial data presented here may not be up to date with the financial markets or represent reality of the information.
We are not liable to you or anyone else if interference with or damage to your computer systems occurs in connection with the use of these Platforms or a linked website. You must take your own precautions to ensure that whatever you select for your use from our Platforms is free of viruses or anything else (such as worms or Trojan horses) that may interfere with or damage the operations of your computer systems.
We may, from time to time and without notice, change or add to the Platforms (including the Terms) or the information, products or services described in it. However, we do not undertake to keep the Platforms updated. We are not liable to you or anyone else if errors occur in the information or the Platforms is not up-to-date.
Our Platforms may contain links to websites operated by third parties. Those links are provided for convenience and may not remain current or be maintained. Unless expressly stated otherwise, we do not endorse and are not responsible for the content on those linked websites and have no control over or rights in those linked websites.
These Platforms are for your personal, non-commercial use only. You may not modify, copy, distribute, transmit, display, perform, reproduce, publish, license, commercially exploit, create derivative works from, transfer, or sell any Content, software, products or services contained within these Platforms. You may not use these Platforms, or any of its Content, to further any commercial purpose, including any advertising or advertising revenue generation activity on your own website.
You must not do any act that we would deem to be inappropriate, is unlawful or is prohibited by any laws applicable to these Platforms, including but not limited to:
If we allow you to post any information to our Platforms, we have the right to take down this information at our sole discretion and without notice.
To the maximum extent permitted by law, we make no warranties or representations about these Platforms or the Content, including but not limited to warranties or representations that they will be complete, accurate or up-to-date, that access will be uninterrupted or error-free or free from viruses, or that these Platforms will be secure.
We reserve the right to restrict, suspend or terminate without notice your access to these Platforms, any Content, or any feature of these Platforms at any time without notice and we will not be responsible for any loss, cost, damage or liability that may arise as a result.
To the maximum extent permitted by law, in no event shall we be liable for any direct and indirect loss, damage or expense – irrespective of the manner in which it occurs – which may be suffered due to your use of our Platforms and/or the information or materials contained on it, or as a result of the inaccessibility of these Platforms and/or the fact that certain information or materials contained on it are incorrect, incomplete or not up-to-date.
This website utilises cookies. If you do not have cookies enabled in your web browser some functions of the site may not work as intended.